| COMPOSITION | |
|---|---|
| Nimesulide | 100MG |
| Serratiopeptidase | 10MG |
NIMESULIDE & SERRATIOPEPTIDASE
NIMOVIB SP
| SPECIFICATION | |
|---|---|
| FORM | TABLET |
| PACKING | 10×10 |
| PACKING TYPE | ALU ALU |
| MRP | |
DESCRIPTION
Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.
SERRATIOPEPTIDASE
Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular infections. Serratiopeptidase is under investigation in clinical trial NCT02493179 (Efficacy Evaluation of the (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery).
SIDE EFFECTS
Oral TDLO (human): 1.429 mg/kg; Oral TDLO (woman): 2 mg/kg; Oral LD50 (rat): 200 mg/kg; Oral LD50 (mouse): 392 mg/kg
INDICATION
For the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.